Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The future of myeloma therapy and where the treatment landscape is moving

Jesús San Miguel • 13 May 2022
COMy 2022
Multiple Myeloma Antibodies CAR-T

Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, briefly explains the future of myeloma treatment and where the landscape will move, drawing focus on novel immunotherapies such as CAR-T therapy and monoclonal antibodies, and the importance of using these therapies at an earlier stage and implementing early intervention. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

More from Jesús San Miguel

Key myeloma highlights from EHA 2023
Enrique Ocio et al. • 9 Jun 2023
1:21
The value of sustained MRD negativity in MM
Jesús San Miguel • 13 May 2022
1:21
MRD evaluation: how, when and for which goal?
Jesús San Miguel • 13 May 2022
4:22
The future myeloma treatment landscape
Jesús San Miguel • 9 Sep 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals